Stomach Cancer Treatment Options

• Stomach cancer treatment typically combines more than one approach — surgery, chemotherapy, targeted therapy, or immunotherapy — chosen by a multidisciplinary care team.
• Treatment plans are personalized based on the cancer’s stage and location, its biomarkers, and the patient’s overall health and preferences.
• Perioperative chemotherapy regimens such as FLOT, HER2-targeted therapy, and immunotherapy for advanced disease have each shown measurable survival benefits in randomized clinical trials.
• Managing treatment side effects proactively, with support from the full care team, is an important part of the treatment journey.

Main Approaches to Stomach Cancer Treatment

The main goals of stomach cancer treatment are to remove or control the cancer and to maintain the patient’s quality of life. Because stomach cancer often calls for more than one type of treatment, care is usually planned by a multidisciplinary team that can include a surgeon, a medical oncologist, and a radiation oncologist.

Surgical Interventions

Surgery is the main treatment for stomach cancer, especially when it is found before it has spread. The type of operation depends on where the tumor is and how much of the stomach it involves. For cancer limited to the lining of the stomach, an endoscopic mucosal resection can sometimes remove it without open surgery. Larger tumors call for a gastrectomy: either a subtotal procedure, taking out only the diseased portion of the stomach and the lymph nodes nearby, or a total gastrectomy, in which the whole stomach comes out and the surgeon then joins the esophagus directly to the small intestine so eating can continue. If a growing tumor has narrowed the passage food normally takes through the stomach, an alternative is to place an expandable stent there, or to reroute digestion surgically with a gastrojejunostomy so food skips the blocked segment entirely.

Systemic Therapies (Chemotherapy, Targeted, Immuno)

Systemic therapies use drugs to treat cancer cells throughout the body and, for earlier-stage disease, are usually paired with surgery rather than used on their own. According to the National Cancer Institute, in the phase III AIO-FLOT4 trial of 716 patients with resectable stage IB to III stomach or gastroesophageal junction cancer, giving chemotherapy both before and after surgery — a perioperative regimen called FLOT (docetaxel, oxaliplatin, fluorouracil, and leucovorin) — produced a median overall survival of 50 months, compared with 35 months for an older perioperative combination. For cancer that has spread beyond the stomach, systemic drug therapy becomes the main treatment.

• Chemotherapy: Commonly used drugs include the fluoropyrimidines fluorouracil (5-FU) and capecitabine, typically paired with a platinum agent such as cisplatin or oxaliplatin.
• Targeted Therapy: According to the National Cancer Institute, in the phase III ToGA trial, about 22% of the 3,665 stomach tumors tested were HER2-positive, and among patients with HER2-positive metastatic or inoperable locally advanced disease, adding trastuzumab to chemotherapy raised median overall survival to 13.8 months, compared with 11.1 months for chemotherapy alone. Tumors that instead test positive for a different marker, Claudin 18.2, and are HER2-negative may be treated with zolbetuximab added to chemotherapy.
• Immunotherapy: Checkpoint inhibitors such as nivolumab and pembrolizumab are used for advanced stomach cancer, usually combined with chemotherapy. Doctors may test the tumor’s PD-L1 score to help predict benefit: in the phase III CheckMate-649 trial of HER2-negative advanced disease, adding nivolumab to chemotherapy extended median overall survival from 11.3 to 14.0 months overall, and from 11.1 to 14.4 months in tumors with a PD-L1 combined positive score of 5 or higher.

Factors Guiding Your Personalized Treatment Plan

Determining the best treatment for stomach cancer involves a comprehensive evaluation by a multidisciplinary team of specialists. Many factors are weighed together, including the cancer’s stage and location, its biomarkers, and the patient’s overall health and preferences.

Cancer Stage and Location

The stage of stomach cancer is one of the most important factors in treatment planning; a separate stomach cancer stages resource covers how each stage is defined. In general, earlier-stage, resectable disease is treated with surgery, often combined with chemotherapy given before and after the operation, while cancer that has spread to distant organs is treated mainly with systemic therapy. The exact location of the tumor within the stomach, such as near the junction with the esophagus versus lower in the stomach, also affects which surgical approach is feasible.

Patient Health and Preferences

A patient’s overall health, including age and other medical conditions, affects how well they can tolerate more intensive treatment; for example, someone with significant heart or kidney problems may not be a candidate for certain chemotherapy regimens. Patient preferences and quality-of-life priorities are part of the discussion too, and open communication between the patient, family, and care team helps ensure the plan reflects the individual’s goals.

Innovations in Gastric Cancer Therapies

A better understanding of the molecular features of stomach cancer has led to newer drug therapies that are now part of standard care for some patients, alongside surgery and traditional chemotherapy.

Advanced Targeted Therapies

Beyond HER2-targeted drugs, biomarker testing can point to other treatable features of a tumor. Zolbetuximab, for instance, is used for metastatic stomach cancer that tests positive for Claudin 18.2 and negative for HER2; added to chemotherapy in the phase III SPOTLIGHT trial, it modestly lengthened both progression-free and overall survival compared with chemotherapy alone. Other targeted drugs used for stomach cancer include trastuzumab deruxtecan, ramucirumab, and regorafenib. Newer targeted agents that are still under study, and not yet part of standard care, are covered on our latest research page.

Immunotherapy Breakthroughs

Checkpoint inhibitors are now part of standard treatment for some patients with advanced stomach cancer. Pembrolizumab is approved for tumors with mismatch-repair deficiency or high microsatellite instability, a pan-cancer approval that applies regardless of where the tumor started. For HER2-positive metastatic disease, trastuzumab may be paired with pembrolizumab and chemotherapy. According to the National Cancer Institute, in the phase III KEYNOTE-811 trial, this combination produced an objective response rate of about 74%, versus about 52% for trastuzumab and chemotherapy without pembrolizumab. Immunotherapy approaches still being tested in trials are covered on our latest research page.

Managing Side Effects of Stomach Cancer Treatment

Stomach cancer treatment aims to be as effective and tolerable as possible, but side effects are still common. Managing them proactively, with support from the care team, helps protect a patient’s quality of life throughout treatment.

Common Physical Side Effects

Side effects differ by treatment type. Because gastrectomy removes part or all of the stomach, changes in eating and digestion afterward are expected, and guidance from a dietitian is usually part of recovery. Chemotherapy often causes nausea, fatigue, hair loss, and mouth sores, since it affects fast-growing healthy cells along with cancer cells. Targeted therapy drugs were once assumed to be gentler than chemotherapy, but the National Cancer Institute points out that they carry their own risks, most often diarrhea, liver problems, and skin rash or dryness. Immunotherapy can trigger immune-related side effects, including flu-like symptoms and inflammation that may involve different organs, which is one reason patients on these drugs are monitored closely.

Support and Coping Strategies

Managing side effects usually involves the whole care team. Nutritional guidance from a dietitian is especially important after gastrectomy, to help with dietary changes and prevent malnutrition. Pain control, anti-nausea medication, and strategies for fatigue are used as needed, and psychological support, such as counseling or support groups, can help patients and families cope with the emotional impact of treatment. Complementary approaches may add comfort but should always be discussed with the care team first, since they are not a substitute for medical treatment.

Frequently Asked Questions

What is the primary goal of stomach cancer treatment?

For earlier-stage, resectable cancer, the goal is usually to remove all detectable disease and prevent recurrence, typically through surgery combined with chemotherapy. For more advanced disease, treatment focuses on controlling the cancer, relieving symptoms, and preserving quality of life.

How is the best treatment for stomach cancer determined?

A multidisciplinary team weighs the cancer’s stage and location, biomarkers such as HER2 status and PD-L1 score, and the patient’s overall health and preferences. Together, these factors guide whether surgery, systemic therapy, or a combination is recommended.

Are there any new treatments for stomach cancer available?

Yes. Targeted drugs such as trastuzumab and zolbetuximab treat tumors with specific biomarkers, and immunotherapy drugs such as nivolumab and pembrolizumab are used for advanced disease, usually combined with chemotherapy. Experimental options still being studied are covered on our latest research page.

Sources

• National Cancer Institute – Stomach (Gastric) Cancer Treatment (PDQ®)–Patient Version
• National Cancer Institute – Stomach (Gastric) Cancer Treatment (PDQ®)–Health Professional Version
• National Cancer Institute – Chemotherapy to Treat Cancer
• National Cancer Institute – Targeted Therapy to Treat Cancer